Trial · NCT07885228
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall response rate (ORR) | Day 28 | The proportion of patients who had a complete response or partial response as compared with baseline organ staging without the use of additional systemic therapy for acute GVHD. |
| Secondary | Durable overall response (DOR) at Day 56 | Day 56 | The proportion of patients who had response at day 28 that was maintained at day 56. |
| Secondary | Best Overall Response (BOR) | Day 56 | The proportion of patients who achieved a complete response or partial response at any time point up to and including Day 56 and before the start of additional systemic therapy for aGVHD. |
| Secondary | Overall response rate (ORR) | Day 56 | The proportion of patients who had a complete response or partial response as compared with baseline organ staging without the use of additional systemic therapy for acute GVHD. |
| Secondary | Overall Survival (OS) | 1 year | The time from the date of enrollment to the date of death due to any cause. |
| Secondary | Failure-Free Survival (FFS) | 1 year | The time from the date of enrollment to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment. |
| Secondary | Relapse-Free Survival (RFS) | 1 year | The interval from enrollment to the date of death from any cause in the absence of hematologic disease relapse or progression. |
| Secondary | Disease Relapse Rate | 1 year | Cumulative incidence of hematological malignancy relapse or progression. |
| Secondary | Event-Free Survival (EFS) | 1 year | Time from the date of enrollment to the date of hematologic disease relapse/progression, graft failure, or death due to any cause. |
| Secondary | Incidence of Chronic Graft-Versus-Host Disease (cGVHD) | 1 year | Cumulative incidence of cGVHD post-allogeneic hematopoietic stem cell transplantation. cGvHD, defined as the diagnosis of any cGvHD including mild, moderate, severe. |
| Secondary | Safety and Tolerability (TEAEs) | Treatment period to 28 days after the last dose of trial treatment. | Evaluation of the safety and tolerability profiles of jaktinib, including the incidence of treatment-related adverse events (TRAEs). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07885228/registered